Our values

1) Access & availability for science & medicine

a) to improve safe, reliable, and affordable patient access to controlled drug medicinal products where clinically appropriate;

b) to improve availability of controlled drug products for legitimate research purposes, particularly where there is high research value;"

2) Evidence development and application

c) to be designed transparently on the basis of evidence reviews on the costs and benefits of a range of drug policy models;

d) to be supported by robust, standardised evaluations to inform continuous policy adaptation and improvement;

e) to systematically collect data on controlled drug use and outcomes across all sectors of access;

3) Harm identification and mitigation

f) to identify potential harms to public health, the individual and wider society;

g) to mitigate identified harms through evidence-based regulations, health interventions and public education;

h) to combat threats to public safety and order associated with organised crime networks;

i) to protect the young and vulnerable from the harms of drug misuse and from any unintended harms caused by policy;

4) Sustainable economic growth

a) to support the growth of legitimate UK industries working with controlled drugs for the public benefit;

b) to meet policy goals cost-effectively and to minimise expenditure on drug control strategies that are not supported by evidence-based reviews.